Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Investor Presentation (July 2026)
26 slides from Hansa Biopharma Ab's investor presentation, July 2026
Slide 1: Corporate Presentation July 2026
® Corporate Presentation July 2026
Slide 2: Forward-looking statements
Forward-looking statements ® This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will o
Slide 3: Novel, first-in-class IgG-cleaving enzyme from proprietary technology platform
Novel, first-in-class IgG-cleaving enzyme from proprietary technology platform ® What is IgG Hansa’s IgG-cleaving Platform Immunoglobulin G (IgG): a protective antibody Imlifidase – proprietary, first in class IgG cleaving enzyme Transplantation / Gene Therapy: High antibody (IgG) Rapid and ta
Slide 4: Unique platform targeting serious immune mediated conditions; rapid IgG reduction
Unique platform targeting serious immune mediated conditions; rapid IgG reduction ® Provides unmatched speed in reducing IgG IgG cleaving enzymes cleave antibodies across all domains Cell bound IgG lowering Intravascular Extravascular IgG IgG IgG modalities Imlifidase HNSA-5487 FcRn inhibitor - PLEX
Slide 5: Addressing orphan and rare autoimmune indications
Addressing orphan and rare autoimmune indications ® THERAPEUTIC FOCUS Desensitization Idefirix conditionally approved in EU & UK For desensitization prior to kidney transplantation with deceased donor Enabling Transplantation Paradigm shift for highly sensitized kidney transplant patients Out-licens
Slide 6: Desensitization: Transplantation
® DESENSITIZATION Transplantation © 2026, Hansa Biopharma AB
Slide 7: US Kidney Transplant: A Growing Market with High Unmet Needs
US Kidney Transplant: A Growing Market with High Unmet Needs ® Significant unmet medical need with thousands of highly sensitized patients waiting for a transplant ~100,000 US Transplant Waitlist is growing people in the US are waiting for a kidney transplant ~45,000 added to the waitlist each year
Slide 8: Robust U.S. commercialization strategy established
Robust U.S. commercialization strategy established ® Concentrated Market Pricing and Reimbursement Experienced US Team ~200 kidney transplant centers 2/3 of patients have Medicare Medical Affairs Focused field-based team with strong transplant market experience Medicare covers kidney transplant vi
Slide 9: Successful US ConfIdeS Phase 3 study
Successful US ConfIdeS Phase 3 study ® Highly statistically significant outcome (p<0.0001) Imlifidase Control Imlifidase Control p-value n n eGFR (mean) eGFR (mean) Primary endpoint 32 32 51.5 19.3 <0.0001 eGFR at 12 months in FAS Rank-based non-parametric analysis of eGFR at 32 32 50.0* 0* 0.0001 1
Slide 10: Summary of ConfIdeS study outcomes
Summary of ConfIdeS study outcomes ® At 1-year post-randomization, desensitization with imlifidase was associated with clinically meaningful and statistically significant kidney function measured as eGFR o 51.5 mL/min/1.73 m2 which was superior to 19.3 mL/min/1.73 m2 in control arm (p<0.0001) Imlifi
Slide 11: Long-term follow-up study showed durable graft and patient survival
Long-term follow-up study showed durable graft and patient survival ® Study Overview Extended pooled analysis from the 17-HMedIdeS-14 study A long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase Key Takeaways (outcomes similar to n
Slide 12: Europe: Positive Data from Post Approval Confirmatory Study (PAES)
Europe: Positive Data from Post Approval Confirmatory Study (PAES) ® PAES Topline Results Current Status in Europe Out-licensing Transaction 50 highly sensitized patients Reimbursement Competitive process for potential transplanted across 23 sites 20+ markets across the EU European partner initi
Slide 13: Transaction Overview: €115 million licensing agreement for Idefirix
Transaction Overview: ® €115 million licensing agreement for Idefirix Transaction Scope Partnership Responsibilities Exclusive out-licensing of Idefirix for transplantation in EU, SERB Pharmaceuticals Hansa Biopharma UK, Switzerland, Norway, Liechtenstein, Iceland and Middle East and North Africa (M
Slide 14: Desensitization: Gene Therapy
® DESENSITIZATION Gene Therapy © 2026, Hansa Biopharma AB
Slide 15: Compelling opportunity in high-growth gene therapy sector
Compelling opportunity in high-growth gene therapy sector ® SIGNIFICANT GROWTH OF GENE CURRENT MARKET Multiple gene therapy drugs THERAPY MARKET OPPORTUNITY with 10 - 40% of patients eligible who cannot be Existing $2B+ market in 2024 ~6,000 patients with current partnerships treated due to AAV ve
Slide 16: Collaborating to bridge access to gene therapies for more patients
Collaborating to bridge access to gene therapies for more patients ® Indication exclusivity Indication exclusivity Current Duchenne Muscular Crigler-Najjar syndrome – partnerships Dystrophy (DMD) - 1/3,500 to ultrarare condition with 5,000 male births worldwide approximate incidence is 0.6- 1 ca
Slide 17: Next generation Compound – Autoimmune Focus HNSA-5487
® Next generation Compound – Autoimmune Focus HNSA-5487 © 2026, Hansa Biopharma AB
Slide 18: Non-human host derived; Phase 1 clinical data
Non-human host derived; Phase 1 clinical data ® Data demonstrated significantly lower immunogenicity for HNSA-5487 with rapid and robust IgG reduction – targeting FDA interaction in 1H 2026 for GBS Study Overview • Double blind, randomized, placebo-controlled trial in 36 healthy volunteers received
Slide 19: Phase 2 Study demonstrated the role imlifidase may play in halting the progression of GBS
Phase 2 Study demonstrated the role imlifidase may play in halting the progression of GBS ® Guillain-Barré Syndrome Phase 2 Study Results A rare, acute, paralyzing, inflammatory disease of the peripheral nervous system caused by the immune Rapid overall improvement in functional system damaging ne
Slide 20: Rare disease focus; IgG mediated conditions
Rare disease focus; IgG mediated conditions ® Guillan Barré Syndrome Significant unmet medical need – nothing approved in the Europe and US US for GBS 13,551 Strong Phase 2 data with imlifidase provides basis for addressable further clinical development 18,564 incidence Submission of IND to FDA and
Slide 21: Financials and Outlook
® FINANCIALS AND OUTLOOK © 2026, Hansa Biopharma AB
Slide 22: Company profile & financial highlights
Company profile & financial highlights ® Idefirix conditionally European out licensing Ended Q2 2026 with 553 MSEK Headquartered in Lund, approved in Europe. PAES transaction to SERB Pharma, in cash, (~ $57 M), proforma for Sweden with offices in data supporting filing for full Euro 115 million valu
Slide 23: Validated, high value pipeline with transformative milestones ahead
Validated, high value pipeline with transformative milestones ahead ® Q2 2026 Q3 2026 Q4 2026 Q1 2027 Filing for full Potential US Potential US ATC US ConfIdeS GBS clinical approval for full data approval of commercial development plan Idefirix with imlifidase launch presentation established EMA Top
Slide 24: Focused Pipeline in Desensitization and Autoimmune Diseases
® Focused Pipeline in Desensitization and Autoimmune Diseases Preclinical Phase 1 Phase 2 Phase 3 Marketed Partner Upcoming Milestone Desensitization Kidney Transplantation Filing with EMA for full approval in Q4 Desensitization Kidney Transplantation PDUFA* date Dec 19, 2026 imlifidase Desensitizat
Slide 25: Experienced and Proven Leadership Team
Experienced and Proven Leadership Team Proven track record delivering growth, approvals, and launches across renal, rare disease, and immunology ® Renée Aguiar-Lucander Maria Törnsén Chief Executive Officer Chief Operating Officer, President US 20+ yrs rare disease leader and former investor, Succes
Slide 26: Hansa Biopharma
3% HAN SAy BIOPHARMA